WUHAN KEQIAN BIOLOGY CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.17 CNY | +2.14% |
|
+1.34% | -10.84% |
| Sales 2024 * | 1.31B 181M 14.45B | Sales 2025 * | 1.6B 221M 17.65B | Capitalization | 8.47B 1.17B 93.21B |
|---|---|---|---|---|---|
| Net income 2024 * | 539M 74.44M 5.93B | Net income 2025 * | 679M 93.78M 7.47B | EV / Sales 2024 * | 6.45 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.28 x |
| P/E ratio 2024 * |
15
x | P/E ratio 2025 * |
12.5
x | Employees | 860 |
| Yield 2024 * |
1.5% | Yield 2025 * |
1.85% | Free-Float | 25.44% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.14% | ||
| 1 week | +1.34% | ||
| Current month | +4.01% | ||
| 1 month | +4.01% | ||
| 3 months | +12.09% | ||
| 6 months | -2.21% | ||
| Current year | -10.84% |
1 week
17.22
18.50
1 month
16.3520.15
Current year
13.9220.61
1 year
13.9226.44
3 years
13.9246.18
5 years
13.9251.11
10 years
13.9251.11
| Managers | Title | Age | Since |
|---|---|---|---|
Mu Lin Chen
CEO | Chief Executive Officer | 36 | 30/04/13 |
Ming Zhong
DFI | Director of Finance/CFO | 41 | 31/08/14 |
Gao Yuan Xu
CTO | Chief Tech/Sci/R&D Officer | 48 | 30/06/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Huan Chun Chen
FOU | Founder | 71 | 10/01/01 |
Hong Lin Wang
BRD | Director/Board Member | 53 | 30/04/19 |
Mei Lin Jin
BRD | Director/Board Member | 70 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 18.17 | +2.14% | 2,610,479 |
| 29/04/24 | 17.79 | +2.30% | 2,705,595 |
| 26/04/24 | 17.39 | -1.31% | 2,130,453 |
| 25/04/24 | 17.62 | -0.79% | 1,988,060 |
| 24/04/24 | 17.76 | +1.14% | 1,311,145 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Wuhan Keqian Biology Co Ltd is a China-based company mainly engaged in the research and development, production, sales of veterinary biological products and the provision of animal epidemic prevention technical services. The Company's main products are vaccines for swine and poultry. The Company mainly conducts its businesses within the China market.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.17
CNY
Average target price
26.04
CNY
Spread / Average Target
+43.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.84% | 1.17B | |
| -9.60% | 6.64B | |
| +24.75% | 3.7B | |
| -3.20% | 3.12B | |
| +2.53% | 1.45B | |
| -15.13% | 1.37B | |
| -25.63% | 1.24B | |
| -6.64% | 1.21B | |
| -.--% | 1.05B | |
| -7.56% | 820M |
- Stock Market
- Equities
- 688526 Stock
